A China-based pharmaceutical company has a headcount of over 7,000 and has more than 40 branches and subsidiaries around the world. The company’s main businesses are in API and generics, although they are rapidly expanding into innovation drug areas such as small molecule drugs, biologics, and cell therapies. The firm has a US subsidiary, an integrated business with capabilities in R&D, manufacturing, and Sales and Marketing. The firm sells generic drugs to major pharmacy chains like CVS and Walgreens, department stores like Walmart and Costco, major grocery stores, etc.
The firm also has an investment subsidiary that conducts equity investments and BD activities (in-licensing, supplier/distributor agreements, etc.) for both the China and US markets.
The firm is most interested in companies developing novel drugs in biologics, cell therapy, gene therapy, repurposed drugs, and biosimilar. In terms of stage of development, companies that are at or before the NDA stage are preferred (Pre-clinical, Phase I, Phase II, Phase III, NDA).
While the firm welcomes proposals on various equity investment and BD opportunities, the firm is currently also interested specifically in the following:
-Late clinical stage assets that can be in-licensed and introduced to the China market;
-Technologies that can be used to improve API production;
-Injectable drugs;
The firm is also interested in distribution rights in China (for both innovation and generic drugs) and in the US (mainly for generic drugs).
The firm has no specific company or management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment